GFP Reporter Cell Line - 8505C

The 8505C cell line is a highly characterized human model of anaplastic thyroid carcinoma (ATC), originally isolated from a primary thyroid tumor of a patient with this exceptionally aggressive and undifferentiated endocrine malignancy. It serves as a cornerstone in thyroid oncology research, particularly valued for its distinct molecular profile—which includes the classic BRAF V600E mutation and a TP53 mutation—making it an essential tool for studying the biology of therapy-resistant, highly proliferative, and metastatic thyroid cancers. The GFP Reporter Cell Line - 8505C is a sophisticated, stably transfected derivative explicitly engineered to express the remarkably bright green fluorescent protein (GFP). This advanced labeling construct ensures continuous, high-level expression of the functional reporter gene across sequential in vitro passages. Crucially, this stable genetic integration is achieved without compromising the fundamental epithelial-like morphology, the specific oncogenic mutation profile, or the intrinsic tumorigenic and aggressive capacity of the original parental 8505C cells.

The incorporation of this fluorescent reporter system significantly broadens the experimental utility of the 8505C model for comprehensive translational thyroid cancer research. For in vitro studies, the intense green fluorescence provided by GFP expression allows researchers to easily visualize cellular dynamics, accurately quantify proliferation rates, perform high-throughput screening assays, and seamlessly isolate specific cellular subpopulations using standard fluorescence microscopy and flow cytometry techniques. For in vivo applications, the robust GFP signal serves as an excellent foundation for tracking primary tumor progression and metastatic dissemination through non-invasive whole-body fluorescence imaging (FLI) or high-resolution ex vivo histological analysis. Because it is a human-derived cell line, the 8505C-GFP model is typically engrafted into immunocompromised mice (such as athymic nude or NSG strains) to establish highly reliable subcutaneous xenografts or clinically relevant orthotopic thyroid models. This specialized reporter line represents an exceptionally valuable platform for evaluating the in vivo therapeutic efficacy of novel chemotherapeutic regimens, targeted pharmacological compounds (such as BRAF and MEK inhibitors), and emerging biotherapeutics aimed at refractory anaplastic thyroid carcinoma, facilitating the accurate quantification of localized tumor burden and disease progression.